Klin Onkol 1993; 6(4): 97-100.
Summary: In stage I and II melanoma only patients considering to be high risks should be considered for entry to adjuvant therapy, but only into clinical trial. No clearly effective adjuvant chemo or immunotherapy for malignant meelanoma has been reported untill now.
